Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Now Covered by Analysts at Stephens

Investment analysts at Stephens initiated coverage on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNMGet Free Report) in a report issued on Tuesday, MarketBeat reports. The brokerage set an “overweight” rating and a $25.00 price target on the biotechnology company’s stock. Stephens’ target price indicates a potential upside of 180.90% from the stock’s previous close.

Several other analysts have also weighed in on the stock. StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, May 5th. Maxim Group increased their price objective on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Actinium Pharmaceuticals in a report on Monday, April 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.60.

Read Our Latest Stock Analysis on Actinium Pharmaceuticals

Actinium Pharmaceuticals Price Performance

Shares of Actinium Pharmaceuticals stock opened at $8.90 on Tuesday. Actinium Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $9.86. The stock has a market capitalization of $265.04 million, a P/E ratio of -5.20 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNMGet Free Report) last issued its quarterly earnings results on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. Equities research analysts anticipate that Actinium Pharmaceuticals will post -1.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brandywine Global Investment Management LLC acquired a new stake in Actinium Pharmaceuticals in the third quarter worth about $1,033,000. Vanguard Group Inc. raised its position in shares of Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock worth $11,325,000 after buying an additional 82,113 shares in the last quarter. Sanders Morris Harris LLC acquired a new stake in shares of Actinium Pharmaceuticals in the 1st quarter worth approximately $78,000. Finally, Creative Financial Designs Inc. ADV lifted its stake in shares of Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares during the period. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

(Get Free Report)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

Further Reading

Analyst Recommendations for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.